How to buy DexCom (DXCM) stocks

DexCom is a medical devices business based in the US. DexCom shares (DXCM) are listed on the NASDAQ and all prices are listed in US Dollars.

Its last market close was $81.62 , which is an increase of 13.9% over the previous week. DexCom employs 10,200 staff and has a trailing 12-month revenue of around $4 billion.

Our top picks for where to buy DexCom stock

Buy DexCom stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Related: Compare the best stock trading platforms in Canada

DexCom stock price (NASDAQ: DXCM)

Use our graph to track the performance of DXCM stocks over time.

DexCom stocks at a glance

• Key figures

Information last updated 2025-05-01.

Latest market close	$81.62
52-week range	$57.52 - $132.26
50-day moving average more info button	$73.43
200-day moving average more info button	$76.45
Wall St. target price	$99.12
PE ratio more info button	49.4789
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$1.42

Is it a good time to buy DexCom stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Dive deeper: Our picks for the best stocks to buy right now in Canada

Is DexCom stock undervalued or overvalued?

Valuing DexCom stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of DexCom's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

DexCom's P/E ratio

DexCom's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 49x. In other words, DexCom shares trade at around 49x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the stock or simply that they're over-valued.

DexCom's PEG ratio

DexCom's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.0967. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into DexCom's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

DexCom's EBITDA

DexCom's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $817.7 million.

The EBITDA is a measure of a DexCom's overall financial performance and is widely used to measure a its profitability.

DexCom financials

Revenue TTM	$4 billion
Operating margin TTM	16.97%
Gross profit TTM	$2.4 billion
Return on assets TTM	5.88%
Return on equity TTM	27.63%
Profit margin	14.29%
Book value	$5.38
Market Capitalization more info button	$27.5 billion

TTM: trailing 12 months

DexCom's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like DexCom.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

DexCom's total ESG risk score

Total ESG risk: 29.18

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and DexCom's overall score of 29.18 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like DexCom is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

DexCom's environmental score

Environmental score: 10.43/100

DexCom's environmental score of 10.43 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

DexCom's social score

Social score: 17.04/100

DexCom's social score of 17.04 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that DexCom is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

DexCom's governance score

Governance score: 13.2/100

DexCom's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that DexCom is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

DexCom's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. DexCom scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that DexCom has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

DexCom Inc was last rated for ESG on: 2019-01-01.

Total ESG score	29.18
Total ESG percentile	50.12
Environmental score	10.43
Environmental score percentile	6
Social score	17.04
Social score percentile	6
Governance score	13.2
Governance score percentile	6
Level of controversy	2

DexCom stock dividends

We're not expecting DexCom to pay a dividend over the next 12 months.

Have DexCom's stocks ever split?

DexCom's stocks were split on a 4:1 basis on 12 June 2022 . So if you had owned 1 share the day before before the split, the next day you'd have owned 4 shares. This wouldn't directly have changed the overall worth of your DexCom stocks – just the quantity. However, indirectly, the new 75% lower stock price could have impacted the market appetite for DexCom stocks, which in turn could have impacted DexCom's stock price.

DexCom stock price volatility

Over the last 12 months, DexCom's stocks have ranged in value from as little as $57.52 up to $132.26. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while DexCom's is 1.504. This would suggest that DexCom's stocks are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

DexCom overview

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Stelo, a new over-the-counter glucose biosensor designed for adults with prediabetes and Type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.

Related: New to stock trading? Compare brokers and get tips for investing.

Frequently asked questions

What percentage of DexCom is owned by insiders or institutions?
Currently 0.406% of DexCom stocks are held by insiders and 96.415% by institutions. How many people work for DexCom?
Latest data suggests 10,200 work at DexCom. When does the fiscal year end for DexCom?
DexCom's fiscal year ends in December. Where is DexCom based?
DexCom's address is: 6340 Sequence Drive, San Diego, CA, United States, 92121 What is DexCom's ISIN number?
DexCom's international securities identification number is: US2521311074 What is DexCom's CUSIP number?
DexCom's Committee on Uniform Securities Identification Procedures number is: 252131107

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.